亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial

医学 微卫星不稳定性 塞来昔布 结直肠癌 临床终点 内科学 肿瘤科 癌症 胃肠病学 封锁 临床试验 生物 微卫星 受体 等位基因 基因 生物化学
作者
Huabin Hu,Liang Kang,Jianwei Zhang,Zehua Wu,Hui Wang,Meijin Huang,Ping Lan,Xiaojian Wu,Chao Wang,Wuteng Cao,Jiancong Hu,Yan Huang,Liang Huang,Huaiming Wang,Lishuo Shi,Yue Cai,Cailu Shen,Jiayu Ling,Xiaoyu Xie,Yonghua Cai
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:7 (1): 38-48 被引量:195
标识
DOI:10.1016/s2468-1253(21)00348-4
摘要

Background PD-1 blockade is highly effective in patients with mismatch repair-deficient or microsatellite instability-high metastatic colorectal cancer. The role of single-agent PD-1 blockade in the neoadjuvant setting for resectable mismatch repair-deficient or microsatellite instability-high colorectal cancer remains unclear. We investigated the efficacy and safety of PD-1 blockade with toripalimab, with or without the COX-2 inhibitor celecoxib, as neoadjuvant treatment for mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancers. Methods The PD-1 Inhibitor in Microsatellite Instability Colorectal Cancer (PICC) trial was a single-centre, open-label, parallel-group, non-comparative, randomised, phase 2 study undertaken at the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Eligible patients were aged 18–75 years, had histologically confirmed mismatch repair-deficient or microsatellite instability-high colorectal cancer, had clinical stage T3–T4 or any T with lymph node positivity (N+), Eastern Cooperative Oncology Group performance score of 0 or 1, and adequate haematological, hepatic, and renal function. Participants were randomly assigned (1:1), without any stratification or balanced blocking, to receive toripalimab 3 mg/kg intravenously on day 1, with or without celecoxib 200 mg orally twice daily from day 1 to 14 of each 14-day cycle, for six cycles before surgical resection. Adjuvant treatment with toripalimab with or without celecoxib was permitted at the investigators' discretion. The primary endpoint was the proportion of patients with pathological complete response, defined as tumours without any viable tumour cells in the resected primary tumour sample and all sampled regional lymph nodes. All efficacy and safety analyses were assessed in the modified intention-to-treat population, which included all patients who were randomly assigned to treatment and who received at least one dose of toripalimab. This trial is registered with ClinicalTrials.gov, NCT03926338, and is ongoing. Findings Between May 1, 2019, and April 1, 2021, 53 patients were screened, of whom 34 were randomly assigned to either the toripalimab plus celecoxib group (n=17) or the toripalimab monotherapy group (n=17). As of data cutoff (Aug 10, 2021), median follow-up was 14·9 months (IQR 8·8–17·0). All patients received study treatment and underwent surgical resection; there were no treatment-related surgical delays. All 34 patients had an R0 resection (>1 mm resection margin). 15 of 17 patients (88% [95% CI 64–99]) in the toripalimab plus celecoxib group and 11 of 17 patients (65% [38–86]) in the toripalimab monotherapy group had a pathological complete response. All patients continued to receive adjuvant toripalimab with or without celecoxib for a total perioperative duration of 6 months and were alive and free of recurrence at data cutoff. During neoadjuvant treatment, ten (59%) patients in the toripalimab plus celecoxib group and ten (59%) in the toripalimab monotherapy group had grade 1–2 treatment-related adverse events. Only one (3%) of 34 patients, who was in the toripalimab plus celecoxib group, had a grade 3 or higher treatment-related adverse event during the neoadjuvant phase, which was grade 3 increased aspartate aminotransferase levels. In the adjuvant phase, only one (3%) of 34 patients, who was in the toripalimab monotherapy group, had a grade 3 or higher treatment-related adverse events, which was grade 3 increased aspartate aminotransferase and alanine aminotransferase levels. Interpretation Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer. This treatment was associated with a high pathological complete response rate and an acceptable safety profile, which did not compromise surgery. Longer term follow-up is needed to assess effects on survival-related endpoints. Funding The National Key R&D Program of China, the National Natural Science Foundation of China, and the Chinese Society of Clinical Oncology-Junshi Biosciences Oncology Immunity Research. Translation For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
3秒前
8秒前
archer01发布了新的文献求助10
12秒前
21秒前
23秒前
Maria完成签到,获得积分10
34秒前
46秒前
TS6539发布了新的文献求助10
53秒前
TS6539完成签到,获得积分10
1分钟前
bababiba完成签到,获得积分10
1分钟前
1分钟前
CipherSage应助archer01采纳,获得10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
2分钟前
量子星尘发布了新的文献求助10
2分钟前
2分钟前
3分钟前
3分钟前
3分钟前
星辰大海应助科研通管家采纳,获得10
3分钟前
4分钟前
量子星尘发布了新的文献求助10
4分钟前
月儿完成签到 ,获得积分10
4分钟前
冬去春来完成签到 ,获得积分10
4分钟前
4分钟前
小江完成签到,获得积分10
4分钟前
gszy1975完成签到,获得积分10
4分钟前
4分钟前
5分钟前
Chaos完成签到 ,获得积分10
5分钟前
光合作用完成签到,获得积分10
5分钟前
5分钟前
5分钟前
5分钟前
八个猪宝贝完成签到,获得积分10
6分钟前
量子星尘发布了新的文献求助10
6分钟前
lameliu完成签到,获得积分10
6分钟前
6分钟前
香蕉觅云应助Viiigo采纳,获得10
6分钟前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3957061
求助须知:如何正确求助?哪些是违规求助? 3503084
关于积分的说明 11111255
捐赠科研通 3234121
什么是DOI,文献DOI怎么找? 1787751
邀请新用户注册赠送积分活动 870772
科研通“疑难数据库(出版商)”最低求助积分说明 802264